local_hospital

Synexus Polska Sp. z o.o.

Address
lock Available on a paid plan

Allergy and Respiratory Research at Synexus Polska Sp. z o.o.

This site is actively involved in respiratory tract diseases and immune system processes, with studies focused on conditions such as asthma, chronic obstructive pulmonary disease, and seasonal allergic rhinitis. The trials are designed to assess new treatment options and better control of symptoms in people with ongoing airway and allergy-related disease.

  • Testing new approaches for uncontrolled asthma and COPD
  • Evaluating relief for seasonal allergic rhinitis and rhinoconjunctivitis
  • Studying long-term management of breathing and allergy symptoms

Research at the Wroclaw site includes both adult and pediatric allergy studies, reflecting a broad effort to improve daily disease control and quality of life.

Dermatology and Immune-Mediated Skin Diseases

A major part of the research portfolio centers on skin and connective tissue diseases and immune system diseases, especially atopic dermatitis, plaque psoriasis, prurigo nodularis, and vitiligo. These trials are mainly aimed at finding more effective ways to reduce inflammation, itching, and visible skin symptoms.

  • Investigating treatments for moderate to severe atopic dermatitis
  • Studying therapies for psoriasis, prurigo nodularis, and vitiligo
  • Assessing long-term safety and symptom control in chronic skin disease

The site contributes to research that helps clarify how new therapies may improve comfort, appearance, and day-to-day functioning for people with persistent inflammatory skin conditions.

Gastroenterology and Liver Disease Studies

Clinical trial activity also covers digestive system diseases and related physiological phenomena, with work in Crohn’s disease, eosinophilic esophagitis, and liver conditions such as NASH and MASH. These studies are intended to evaluate whether new therapies can improve disease control, support tissue healing, and slow progression of chronic gastrointestinal and liver disorders.

  • Testing treatments for Crohn’s disease and eosinophilic esophagitis
  • Evaluating therapies for NASH and MASH with fibrosis
  • Measuring long-term benefit in chronic digestive and liver disease

This area shows a strong focus on conditions that can affect nutrition, comfort, and long-term organ health.

Cardiometabolic and Kidney Research

The site runs multiple trials in cardiovascular diseases, nutritional and metabolic diseases, and kidney-related conditions. Main diseases under study include hypertension, hyperlipidemia, obesity, type 2 diabetes mellitus, and chronic kidney disease, with research aimed at reducing future heart and kidney complications.

  • Evaluating therapies for high cardiovascular risk and established heart disease
  • Studying treatment options for CKD, hypertension, and metabolic imbalance
  • Assessing approaches to lower LDL cholesterol and improve cardiometabolic health

These trials reflect a broad effort to improve prevention and long-term outcomes in people at risk of serious vascular and metabolic disease.

Autoimmune, Rheumatology, and Pain Research

Another important research stream includes immune system diseases, musculoskeletal diseases, and musculoskeletal and neural physiological phenomena. Studies are being conducted in psoriatic arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, osteoporosis, and chronic nerve pain, with the goal of improving symptom control and long-term disease management.

  • Testing new therapies for psoriatic arthritis and lupus
  • Comparing treatment options for postmenopausal osteoporosis
  • Studying relief for chronic neuropathic pain

At Synexus Polska Sp. z o.o., these studies support research into conditions that can affect mobility, daily comfort, and long-term quality of life.

Infectious Disease and Vaccine Research

The portfolio includes work in bacterial infections and mycoses and virus diseases, with studies related to respiratory syncytial virus, recurrent herpes labialis, and prevention of invasive extraintestinal pathogenic Escherichia coli disease. These trials aim to improve prevention, strengthen immune protection, and evaluate whether new or combined vaccine strategies can provide better protection.

  • Assessing vaccine responses for RSV and influenza
  • Studying prevention of ExPEC disease
  • Evaluating treatment for recurrent herpes labialis

This area highlights the site’s role in both treatment and prevention research for common and potentially serious infectious diseases.

Neurology, Cognitive Health, and Post-Viral Conditions

The site also supports research in nervous system diseases and related cognitive outcomes, including cognitive impairment associated with post-COVID-19 syndrome and chronic pain syndromes affecting the nervous system. These studies are designed to see whether new therapies can improve thinking, memory, and symptom burden after infection or nerve injury.

  • Evaluating treatments for post-COVID cognitive impairment
  • Studying therapies for chronic peripheral neuropathic pain
  • Exploring ways to improve everyday cognitive function and comfort

The research adds an important dimension to the site’s broader clinical program by addressing conditions that can be difficult to diagnose and manage.

Site Overview

assignment
10
connected trials
corporate_fare
12
sponsors
science
30
IMPs

Activity Indicator

Last 6 months

0
Trials started
0
Trials started 6–12 months ago
10
Total trials linked
Highly Active
trending_flatStable0%
Mar
Apr
May
Jun
Jul
Aug

Trial Flow

How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.

Therapeutic areaarrow_forwardIMParrow_forwardLifecycle status

Top 5 of 7 therapeutic areas and 15 of 30 IMPs, ranked by number of trials.

lock Available on a paid plan

Compounds & Molecules Timeline

The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.

Trial span Ongoing Showing last 8 years
lock Available on a paid plan

Sponsor & Partnership

Top sponsors by active trials, and the ones that have come back for more than one study.

Active trials
4
Sponsors (total)
12
Active sponsors
4

Sponsor Network

Top 4 by active trials.

lock +3 more on a paid plan

Partnership History

Sponsors with repeated collaboration (≥ 2 trials).

No repeated partnerships found.

Sponsor Network Graph

How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.

Country Benchmark

Compared to 1 624 other sites in Poland

description
Trial volume
10
Outperforms 78% of sites
public
Therapeutic diversity
7areas
Outperforms 90% of sites
groups
Sponsor diversity
12sponsors
Outperforms 85% of sites

Therapeutic Area Benchmark — Poland

Select a therapeutic area to compare against other sites in Poland.

Competitor Comparison

Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.

Country: Poland

Market Share

Country: Poland

Therapeutic Area Market Share

Select a therapeutic area to view its disease coverage breakdown.

Heat Maps & Advanced Analytics

How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.

Other Trials in Synexus Polska Sp. z o.o.

lock Showing 1 of 10 trials — the rest is available on a paid plan.

Trial Sponsor Phase Status Start Date End Date
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus ErythematosusBristol Myers Squibb International CorporationPhase IINot RecruitingMay 2019Mar 2025

IMP list

lock Showing 1 of 30 compounds — the rest is available on a paid plan.

IMP Trials Status First start Last start
A/Victoria/2570/2019 (H1N1)Pdm09-Like Strain (A/Victoria/2570/2019, Ivr-215)1Unknown2023-11-062023-11-06

Upgrade this site to Business Plan

Own the profile, publish your feasibility data and reach sponsors directly.

Is something out of date?

Tell us what needs correcting and we'll update this profile.

lock Available to Business plan sites only.